Targeting prostacyclin to inhibit platelet activation; MRD-tailored myeloma maintenance; AREG and HSC function in DNA damage repair deficiency and aging

episode

Blood Podcast not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

ON-AIR 🟢 - Poo-tane Gas 50 min · 23 Sep 2026 · The Morning Rumble

Lemon LIVE at 5: Trump's Attack on the Media is an Attack on Democracy 57 min · 23 Sep 2026 · The Don Lemon Show

Iran's President Addresses the UN General Assembly 3 min · 23 Sep 2026 · Fox News Hourly Update

NPR News: 09-23-2026 6PM EDT 5 min · 23 Sep 2026 · NPR News Now

Matheson on Guerrero Jr.'s contract comments, his season performance and the optics of the statement 10 min · 23 Sep 2026 · OverDrive

H3 Tim Grunhard 39 min · 23 Sep 2026 · The Program

Report any issue

Source

Recorded02 Nov 2023

Publisherfeeds.transistor.fm ↗

Handlerec:11741999

Show notes

In this week's episode we'll see how targeting the prostacyclin receptor is a promising strategy for regulating hemostasis and thrombosis. Then, we'll learn how new evidence indicates that the progression rate is low in MRD-negative myeloma patients who discontinue post-transplant lenalidomide and dexamethasone maintenance therapy after 2 years. Finally we'll discuss how amphiregulin from leptin receptor-positive niche cells in the bone marrow mediates crosstalk between the niche and hematopoietic stem cells under conditions of DNA repair deficiency and aging.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in